Oncology biomarkers for gynecologic malignancies

Frontiers in Bioscience - Elite

Volumn 4 E, Issue 3, 2012, Pages 1097-1110

  Tanyi, Janos L ^a   Scholler, Nathalie ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

CA125; CEA; Disease monitoring; Early detection; Gynecologic malignancies; HCG; HE4; KLK; Mesothelin; Oncology biomarkers; Review

Indexed keywords

ACTIVIN; ALPHA FETOPROTEIN; BIOLOGICAL MARKER; CA 125 ANTIGEN; CA 15-3 ANTIGEN; CA 19-9 ANTIGEN; CA 72-4 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CHORIONIC GONADOTROPIN; CHORIONIC GONADOTROPIN BETA SUBUNIT; CYTOKERATIN 19 FRAGMENT; HUMAN EPIDIDYMIS PROTEIN 4; INHIBIN; KALLIKREIN; LYSOPHOSPHATIDIC ACID; MESOTHELIN; OSTEOPONTIN; SERUM AMYLOID A; SQUAMOUS CELL CARCINOMA ANTIGEN; TUMOR MARKER;

ALGORITHM; ALPHA FETOPROTEIN BLOOD LEVEL; ARTICLE; ENDOMETRIUM CANCER; HORMONE BLOOD LEVEL; HUMAN; OVARY CARCINOMA; TROPHOBLASTIC TUMOR; UTERINE CERVIX CANCER; FEMALE; FEMALE GENITAL TRACT TUMOR; METABOLISM;

FEMALE; GENITAL NEOPLASMS, FEMALE; HUMANS; TUMOR MARKERS, BIOLOGICAL;

EID: 84860870599     PISSN: 19450494     EISSN: 19450508     Source Type: Journal    
DOI: None     Document Type: Article

References (146)

1. P. D. Wagner, M. Verma and S. Srivastava: Challenges for biomarkers in cancer detection. Ann N Y Acad Sci, 1022, 9-16 (2004) (Pubitemid 38951575)
2. R. C. Bast, T. L. Klug, E. Schaetzl, P. Lavin, J. M. Niloff, T. F. Greber, V. R. Zurawski, Jr. and R. C. Knapp: Monitoring human ovarian carcinoma with a combination of CA 125, CA 19-9, and carcinoembryonic antigen. Am J Obstet Gynecol, 149(5), 553-9 (1984) (Pubitemid 14086185)
3. E. C. Kohn, N. Azad, C. Annunziata, A. S. Dhamoon and G. Whiteley: Proteomics as a tool for biomarker discovery. Dis Markers, 23(5-6), 411-7 (2007) (Pubitemid 350171262)
4. G. L. Anderson, M. McIntosh, L. Wu, M. Bernett, G. E. Goodman, J. D. Thorpe, L. Bergan, M. D. Thornquist, N. Scholler, N. W. Kim, K. C. O'Briant, C. Drescher and N. Urban: Assessing Lead Time of Selected Ovarian Cancer Biomarkers: A Nested Case -Control Study. J Natl Cancer Inst, 102, 26-38 (2010)
5. M. Shih Ie and R. J. Kurman: Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol, 164(5), 1511-8 (2004) (Pubitemid 38529752)
6. S. J. Skates and D. E. Singer: Quantifying the potential benefit of CA 125 screening for ovarian cancer. J Clin Epidemiol, 44(4-5), 365-80 (1991)
7. R. C. Bast, M. Feeney, H. Lazarus, L. M. Nadler, R. B. Colvin and R. C. Knapp: Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest, 68(5), 1331-7 (1981) (Pubitemid 12235035)
8. R. C. Bast, D. Badgwell, Z. Lu, R. Marquez, D. Rosen, J. Liu, K. A. Baggerly, E. N. Atkinson, S. Skates, Z. Zhang, A. Lokshin, U. Menon, I. Jacobs and K. Lu: New tumor markers: CA125 and beyond. Int J Gynecol Cancer, 15 Suppl 3, 274-81 (2005) (Pubitemid 43096594)
9. E. L. Moss, J. Hollingworth and T. M. Reynolds: The role of CA125 in clinical practice. J Clin Pathol, 58(3), 308-12 (2005) (Pubitemid 40380329)
10. N. Scholler and N. Urban: CA125 in Ovarian Cancer. Biomarkers in Medicine, 1(4), 513-523 (2007)
11. R. C. Bast, T. L. Klug, E. St John, E. Jenison, J. M. Niloff, H. Lazarus, R. S. Berkowitz, T. Leavitt, C. T. Griffiths, L. Parker, V. R. Zurawski, Jr. and R. C. Knapp: A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med, 309(15), 883-7 (1983) (Pubitemid 13014028)
12. B. W. Yin and K. O. Lloyd: Molecular cloning of the CA125 ovarian cancer antigen: identification as a new mucin, MUC16. J Biol Chem, 276(29), 27371-5 (2001)
13. B. W. Yin, A. Dnistrian and K. O. Lloyd: Ovarian cancer antigen CA125 is encoded by the MUC16 mucin gene. Int J Cancer, 98(5), 737-40 (2002) (Pubitemid 34225625)
14. R. C. Bast, N. Urban, V. Shridhar, D. Smith, Z. Zhang, S. Skates, K. Lu, J. Liu, D. Fishman and G. Mills: Early detection of ovarian cancer: promise and reality. Cancer Treat Res, 107, 61-97 (2002)
15. R. C. Bast, Jr.: Status of tumor markers in ovarian cancer screening. J Clin Oncol, 21(10 Suppl), 200s-205s (2003)
16. D. G. Rosen, L. Wang, J. N. Atkinson, Y. Yu, K. H. Lu, E. P. Diamandis, I. Hellstrom, S. C. Mok, J. Liu and R. C. Bast, Jr.: Potential markers that complement expression of CA125 in epithelial ovarian cancer. Gynecol Oncol, 99(2), 267-77 (2005) (Pubitemid 41502830)
17. I. Jacobs: Screening for ovarian cancer by CA-125 measurement. Lancet, 1(8590), 889 (1988) (Pubitemid 18092438)
18. R. E. Hawkins, K. Roberts, E. Wiltshaw, J. Mundy, I. J. Fryatt and V. R. McCready: The prognostic significance of the half-life of serum CA 125 in patients responding to chemotherapy for epithelial ovarian carcinoma. Br J Obstet Gynaecol, 96(12), 1395-9 (1989) (Pubitemid 20020045)
19. P. Fioretti, A. Gadducci, M. Ferdeghini, C. Prontera, G. Malagnino, V. Facchini, G. Mariani and R. Bianchi: The concomitant determination of different serum tumor markers in epithelial ovarian cancer: relevance for monitoring the response to chemotherapy and follow-up of patients. Gynecol Oncol, 44(2), 155-60 (1992)
20. S. J. Skates, F. J. Xu, Y. H. Yu, K. Sjovall, N. Einhorn, Y. Chang, R. C. Bast, Jr. and R. C. Knapp: Toward an optimal algorithm for ovarian cancer screening with longitudinal tumor markers. Cancer, 76(10 Suppl), 2004-10 (1995)
21. N. Einhorn: Ovarian cancer. Early diagnosis and screening. Hematol Oncol Clin North Am, 6(4), 843-50 (1992)
22. R. E. Hawkins, K. Roberts, E. Wiltshaw, J. Mundy and V. R. McCready: The clinical correlates of serum CA125 in 169 patients with epithelial ovarian carcinoma. Br J Cancer, 60(4), 634-7 (1989) (Pubitemid 19251466)
23. G. J. Rustin, A. E. Nelstrop, P. McClean, M. F. Brady, W. P. McGuire, W. J. Hoskins, H. Mitchell and H. E. Lambert: Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125. J Clin Oncol, 14(5), 1545-51 (1996) (Pubitemid 26134212)
24. G. J. Rustin, A. E. Nelstrop, M. Crawford, J. Ledermann, H. E. Lambert, R. Coleman, J. Johnson, H. Evans, S. Brown and W. Oster: Phase II trial of oral altretamine for relapsed ovarian carcinoma: evaluation of defining response by serum CA125. J Clin Oncol, 15(1), 172-6 (1997) (Pubitemid 27020570)
25. R. C. Bast, M. Brewer, C. Zou, M. A. Hernandez, M. Daley, R. Ozols, K. Lu, Z. Lu, D. Badgwell, G. B. Mills, S. Skates, Z. Zhang, D. Chan, A. Lokshin and Y. Yu: Prevention and early detection of ovarian cancer: mission impossible? Recent Results Cancer Res, 174, 91-100 (2007)
26. J. K. Gohagan, P. C. Prorok, R. B. Hayes, B. S. Kramer: The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial of the National Cancer Institute: history, organization, and status. Control Clin Trials, 21(6 Suppl), 251S-272S (2000)
27. M. A. Hasson, R. M. Fagerstrom, D. C. Kahane, J. H. Walsh, M. H. Myers, C. Caughman, B. Wenzel, J. C. Haralson, L. M. Flickinger, L. M. Turner: Design and evolution of the data management systems in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Control Clin Trials, 21(6 Suppl), 329S-348S (2000)
28. R. B. Hayes, D. Reding, W. Kopp, A. F. Subar, N. Bhat, N. Rothman, N. Caporaso, R. G. Ziegler, C. C. Johnson, J. L. Weissfeld, R. N. Hoover, P. Hartge, C. Palace, J. K. Gohagan and L. C. a. O. C. S. T. P. T. Prostate: Etiologic and early marker studies in the prostate, lung, colorectal and ovarian (PLCO) cancer screening trial. Control Clin Trials, 21(6 Suppl), 349S-355S (2000)
29. E. Partridge, A. R. Kreimer, R. T. Greenlee, C. Williams, J. L. Xu, T. R. Church, B. Kessel, C. C. Johnson, J. L. Weissfeld, C. Isaacs, G. L. Andriole, S. Ogden, L. R. Ragard, S. S. Buys and P. P. Team: Results from four rounds of ovarian cancer screening in a randomized trial. Obstet Gynecol, 113(4), 775-82 (2009)
30. G. L. Anderson, M. McIntosh, L. Wu, M. Barnett, G. Goodman, J. D. Thorpe, L. Bergan, M. D. Thornquist, N. Scholler, N. Kim, K. O'Briant, C. Drescher and N. Urban: Assessing lead time of selected ovarian cancer biomarkers: a nested case-control study. J Natl Cancer Inst, 102(1), 26-38 (2010)
31. J. T. Soper, V. J. Hunter, L. Daly, M. Tanner, W. T. Creasman and R. C. Bast, Jr.: Preoperative serum tumorassociated antigen levels in women with pelvic masses. Obstet Gynecol, 75(2), 249-54 (1990) (Pubitemid 20062243)
32. Z. Zhang, S. D. Barnhill, H. Zhang, F. Xu, Y. Yu, I. Jacobs, R. P. Woolas, A. Berchuck, K. R. Madyastha and R. C. Bast, Jr.: Combination of multiple serum markers using an artificial neural network to improve specificity in discriminating malignant from benign pelvic masses. Gynecol Oncol, 73(1), 56-61 (1999) (Pubitemid 29177600)
33. U. H. Stenman, H. Alfthan, J. Vartiainen and P. Lehtovirta: Markers supplementing CA 125 in ovarian cancer. Ann Med, 27(1), 115-20 (1995)
34. W. J. Hoskins: Principles and practice of gynecologic oncology. Lippincott Williams & Wilkins, Philadelphia (2005)
35. R. C. Bast, S. Knauf, A. Epenetos, B. Dhokia, L. Daly, M. Tanner, J. Soper, W. Creasman, S. Gall, R. C. Knapp and et al.: Coordinate elevation of serum markers in ovarian cancer but not in benign disease. Cancer, 68(8), 1758-63 (1991)
36. G. Scambia, P. Benedetti Panici, G. Baiocchi, L. Perrone, S. Greggi, P. Di Roberto and S. Mancuso: CA 15-3 serum levels in ovarian cancer. Oncology, 45(3), 263-7 (1988)
37. U. Hasholzner, L. Baumgartner, P. Stieber, W. Meier, W. Reiter, H. Pahl and A. Fateh-Moghadam: Clinical significance of the tumour markers CA 125 II and CA 72-4 in ovarian carcinoma. Int J Cancer, 69(4), 329-34 (1996) (Pubitemid 26298300)
38. M. S. Lenhard, S. Nehring, D. Nagel, D. Mayr, A. Kirschenhofer, L. Hertlein, K. Friese, P. Stieber and A. Burges: Predictive value of CA 125 and CA 72-4 in ovarian borderline tumors. Clin Chem Lab Med, 47(5), 537-42 (2009)
39. E. M. Schutter, C. Sohn, P. Kristen, V. Mobus, G. Crombach, M. Kaufmann, H. Caffier, R. Kreienberg, A. A. Verstraeten and P. Kenemans: Estimation of probability of malignancy using a logistic model combining physical examination, ultrasound, serum CA 125, and serum CA 72-4 in postmenopausal women with a pelvic mass: an international multicenter study. Gynecol Oncol, 69(1), 56-63 (1998)
40. P. M. Gocze, D. G. Szabo, G. N. Than, I. F. Csaba and K. F. Krommer: Occurrence of CA 125 and CA 19-9 tumor-associated antigens in sera of patients with gynecologic, trophoblastic, and colorectal tumors. Gynecol Obstet Invest, 25(4), 268-72 (1988)
41. A. Gadducci, M. Ferdeghini, C. Prontera, L. Moretti, G. Mariani, R. Bianchi and P. Fioretti: The concomitant determination of different tumor markers in patients with epithelial ovarian cancer and benign ovarian masses: relevance for differential diagnosis. Gynecol Oncol, 44(2), 147-54 (1992)
42. K. Tamakoshi, F. Kikkawa, K. Shibata, K. Tomoda, N. H. Obata, F. Wakahara, Y. Tokuhashi, H. Ishikawa, M. Kawai and Y. Tomoda: Clinical value of CA125, CA19-9, CEA, CA72-4, and TPA in borderline ovarian tumor. Gynecol Oncol, 62(1), 67-72 (1996) (Pubitemid 26234547)
43. M. J. Goldstein and E. P. Mitchell: Carcinoembryonic antigen in the staging and follow-up of patients with colorectal cancer. Cancer Invest, 23(4), 338-51 (2005) (Pubitemid 41656973)
44. L. D. Roman, L. I. Muderspach, A. F. Burnett and C. P. Morrow: Carcinoembryonic antigen in women with isolated pelvic masses. Clinical utility? J Reprod Med, 43(5), 403-7 (1998) (Pubitemid 28244003)
45. M. T. Galgano, G. M. Hampton and H. F. Frierson, Jr.: Comprehensive analysis of HE4 expression in normal and malignant human tissues. Mod Pathol, 19(6), 847-53 (2006) (Pubitemid 43780455)
46. W. Burke, M. Daly, J. Garber, J. Botkin, M. J. Kahn, P. Lynch, A. McTiernan, K. Offit, J. Perlman, G. Petersen, E. Thomson and C. Varricchio: Recommendations for followup care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2. Cancer Genetics Studies Consortium. JAMA, 277(12), 997-1003 (1997) (Pubitemid 27142370)
47. I. Hellstrom, J. Raycraft, M. Hayden-Ledbetter, J. A. Ledbetter, M. Schummer, M. McIntosh, C. Drescher, N. Urban and K. E. Hellstrom: The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res, 63(13), 3695-700 (2003) (Pubitemid 36793054)
48. L. A. Cole: New discoveries on the biology and detection of human chorionic gonadotropin. Reprod Biol Endocrinol, 7, 8 (2009)
49. L. A. Cole, A. Tanaka, G. S. Kim, S. Y. Park, M. W. Koh, P. E. Schwartz, J. T. Chambers and J. H. Nam: Betacore fragment (beta-core/UGF/UGP), a tumor marker: a 7-year report. Gynecol Oncol, 60(2), 264-70 (1996) (Pubitemid 26058771)
50. M. Kinugasa, R. Nishimura, T. Koizumi, K. Morisue, T. Higashida, T. Natazuka, T. Nakagawa, T. Isobe, S. Baba and K. Hasegawa: Combination assay of urinary beta-core fragment of human chorionic gonadotropin with serum tumor markers in gynecologic cancers. Jpn J Cancer Res, 86(8), 783-9 (1995)
51. C. Y. Muller and L. A. Cole: The quagmire of hCG and hCG testing in gynecologic oncology. Gynecol Oncol, 112(3), 663-72 (2009)
52. D. Badgwell and R. C. Bast, Jr.: Early detection of ovarian cancer. Dis Markers, 23(5-6), 397-410 (2007) (Pubitemid 350171267)
53. C. Lottersberger, R. Hoermann, K. Mann, S. Schwarz and P. Berger: Tumor-and pregnancy-derived isoforms of human chorionic gonadotropin: biological and diagnostic relevance. Horm Res, 59(3), 125-34 (2003) (Pubitemid 36359409)
54. M. Kawai, T. Kano, F. Kikkawa, Y. Morikawa, H. Oguchi, N. Nakashima, T. Ishizuka, K. Kuzuya, M. Ohta, Y. Arii and et al.: Seven tumor markers in benign and malignant germ cell tumors of the ovary. Gynecol Oncol, 45(3), 248-53 (1992)
55. S. N. Chow, J. H. Yang, Y. H. Lin, Y. P. Chen, J. I. Lai, R. J. Chen and C. D. Chen: Malignant ovarian germ cell tumors. Int J Gynaecol Obstet, 53(2), 151-8 (1996)
56. Y. Zalel, B. Piura, U. Elchalal, B. Czernobilsky, S. Antebi and R. Dgani: Diagnosis and management of malignant germ cell ovarian tumors in young females. Int J Gynaecol Obstet, 55(1), 1-10 (1996) (Pubitemid 26343457)
57. G. Olt, A. Berchuck and R. C. Bast, Jr.: The role of tumor markers in gynecologic oncology. Obstet Gynecol Surv, 45(9), 570-7 (1990) (Pubitemid 20291724)
58. R. E. Lappohn, H. G. Burger, J. Bouma, M. Bangah, M. Krans and H. W. de Bruijn: Inhibin as a marker for granulosa-cell tumors. N Engl J Med, 321(12), 790-3 (1989) (Pubitemid 19237426)
59. J. F. Boggess, M. R. Soules, B. A. Goff, B. E. Greer, J. M. Cain and H. K. Tamimi: Serum inhibin and disease status in women with ovarian granulosa cell tumors. Gynecol Oncol, 64(1), 64-9 (1997) (Pubitemid 27026958)
60. H. G. Burger, A. Baillie, A. E. Drummond, D. L. Healy, T. Jobling, P. Mamers, D. M. Robertson, B. Susil, N. Cahir, Y. Shen, K. Verity, P. J. Fuller, N. P. Groome and J. K. Findlay: Inhibin and ovarian cancer. J Reprod Immunol, 39(1-2), 77-87 (1998) (Pubitemid 28418415)
61. U. Menon, S. C. Riley, J. Thomas, C. Bose, A. Dawnay, L. W. Evans, N. P. Groome and I. J. Jacobs: Serum inhibin, activin and follistatin in postmenopausal women with epithelial ovarian carcinoma. BJOG, 107(9), 1069-74 (2000)
62. G. M. Lambert-Messerlian, M. Steinhoff, W. Zheng, J. A. Canick, W. H. Gajewski, D. B. Seifer and A. L. Schneyer: Multiple immunoreactive inhibin proteins in serum from postmenopausal women with epithelial ovarian cancer. Gynecol Oncol, 65(3), 512-6 (1997) (Pubitemid 27255997)
63. H. Kato and T. Torigoe: Radioimmunoassay for tumor antigen of human cervical squamous cell carcinoma. Cancer, 40(4), 1621-8 (1977) (Pubitemid 8221737)
64. T. Maruo, S. Yoshida, T. Samoto, Y. Tateiwa, X. Peng, S. Takeuchi and S. Motoyama: Factors regulating SCC antigen expression in squamous cell carcinoma of the uterine cervix. Tumour Biol, 19(6), 494-504 (1998) (Pubitemid 28539333)
65. G. Scambia, P. Benedetti, E. Foti, G. Ferrandina, F. P. Leone, M. Marciano and S. Mancuso: Multiple tumour marker assays in advanced cervical cancer: relationship to chemotherapy response and clinical outcome. Eur J Cancer, 32A(2), 259-63 (1996)
66. N. Takeshima, Y. Hirai, K. Katase, K. Yano, K. Yamauchi and K. Hasumi: The value of squamous cell carcinoma antigen as a predictor of nodal metastasis in cervical cancer. Gynecol Oncol, 68(3), 263-6 (1998) (Pubitemid 28183497)
67. P. M. Gocze, H. W. Vahrson and D. A. Freeman: Serum levels of squamous cell carcinoma antigen and ovarian carcinoma antigen (CA 125) in patients with benign and malignant diseases of the uterine cervix. Oncology, 51(5), 430-4 (1994) (Pubitemid 24255308)
68. B. G. Kim, J. H. Kim, S. Y. Park, J. H. Lee, E. D. Lee, K. H. Lee, K. B. Park, B. H. Lee and K. H. Kim: Relationship between squamous cell carcinoma antigen levels and tumor volumes in patients with cervical carcinomas undergoing neoadjuvant chemotherapy. Gynecol Oncol, 63(1), 105-13 (1996)
69. J. H. Hong, C. S. Tsai, J. T. Chang, C. C. Wang, C. H. Lai, S. P. Lee, C. J. Tseng, T. C. Chang and S. G. Tang: The prognostic significance of pre-and posttreatment SCC levels in patients with squamous cell carcinoma of the cervix treated by radiotherapy. Int J Radiat Oncol Biol Phys, 41(4), 823-30 (1998) (Pubitemid 28285960)
70. J. M. Duk, P. C. van Voorst Vader, K. A. ten Hoor, H. Hollema, H. M. Doeglas and H. W. de Bruijn: Elevated levels of squamous cell carcinoma antigen in patients with a benign disease of the skin. Cancer, 64(8), 1652-6 (1989) (Pubitemid 19251134)
71. J. M. Duk, H. W. De Bruijn, K. H. Groenier, G. J. Fleuren and J. G. Aalders: Adenocarcinoma of the uterine cervix. Prognostic significance of pretreatment serum CA 125, squamous cell carcinoma antigen, and carcinoembryonic antigen levels in relation to clinical and histopathologic tumor characteristics. Cancer, 65(8), 1830-7 (1990) (Pubitemid 20116659)
72. G. Borras, R. Molina, J. Xercavins, A. Ballesta and J. Iglesias: Tumor antigens CA 19.9, CA 125, and CEA in carcinoma of the uterine cervix. Gynecol Oncol, 57(2), 205-11 (1995)
73. A. Leminen, H. Alftan, U. H. Stenman and P. Lehtovirta: Chemotherapy as initial treatment for cervical carcinoma: clinical and tumor marker response. Acta Obstet Gynecol Scand, 71(4), 293-7 (1992)
74. A. Jemal, R. Siegel, E. Ward, Y. Hao, J. Xu, T. Murray and M. J. Thun: Cancer statistics, 2008. CA Cancer J Clin, 58(2), 71-96 (2008) (Pubitemid 351521864)
75. K. S. Matthews, J. M. Estes, M. G. Conner, U. Manne, J. M. Whitworth, W. K. Huh, R. D. Alvarez, J. M. Straughn, M. N. Barnes and R. P. Rocconi: Lynch syndrome in women less than 50 years of age with endometrial cancer. Obstet Gynecol, 111(5), 1161-6 (2008) (Pubitemid 351620352)
76. K. Garg, K. Shih, R. Barakat, Q. Zhou, A. Iasonos and R. A. Soslow: Endometrial carcinomas in women aged 40 years and younger: tumors associated with loss of DNA mismatch repair proteins comprise a distinct clinicopathologic subset. Am J Surg Pathol, 33(12), 1869-77 (2009)
77. E. P. Beck, M. Wagner, L. Anselmino, F. Xu, R. C. Bast, Jr. and W. Jaeger: Is OVX1 a suitable marker for endometrial cancer? Gynecol Oncol, 65(2), 291-6 (1997) (Pubitemid 27216943)
78. H. Hareyama, N. Sakuragi, S. Makinoda and S. Fujimoto: Serum and tissue measurements of CA72-4 in patients with endometrial carcinoma. J Clin Pathol, 49(12), 967-70 (1996) (Pubitemid 27273805)
79. P. L. Cherchi, S. Dessole, G. A. Ruiu, G. Ambrosini, M. Farina, G. Capobianco and A. Ambrosini: The value of serum CA 125 and association CA 125/CA 19-9 in endometrial carcinoma. Eur J Gynaecol Oncol, 20(4), 315-7 (1999) (Pubitemid 30113736)
80. R. G. Moore, A. K. Brown, M. C. Miller, S. Skates, W. J. Allard, T. Verch, M. Steinhoff, G. Messerlian, P. DiSilvestro, C. O. Granai and R. C. Bast, Jr.: The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol, 108(2), 402-8 (2008) (Pubitemid 351174295)
81. J. M. Duk, J. G. Aalders, G. J. Fleuren and H. W. de Bruijn: CA 125: a useful marker in endometrial carcinoma. Am J Obstet Gynecol, 155(5), 1097-102 (1986) (Pubitemid 17176689)
82. A. K. Sood, R. E. Buller, R. A. Burger, J. D. Dawson, J. I. Sorosky and M. Berman: Value of preoperative CA 125 level in the management of uterine cancer and prediction of clinical outcome. Obstet Gynecol, 90(3), 441-7 (1997) (Pubitemid 27357939)
83. C. H. Hsieh, C. C. ChangChien, H. Lin, E. Y. Huang, C. C. Huang, K. C. Lan and S. Y. Chang: Can a preoperative CA 125 level be a criterion for full pelvic lymphadenectomy in surgical staging of endometrial cancer? Gynecol Oncol, 86(1), 28-33 (2002) (Pubitemid 34757047)
84. J. L. Powell, K. A. Hill, B. C. Shiro, S. J. Diehl and W. H. Gajewski: Preoperative serum CA-125 levels in treating endometrial cancer. J Reprod Med, 50(8), 585-90 (2005) (Pubitemid 41193137)
85. A. Gadducci, S. Cosio, A. Carpi, A. Nicolini and A. R. Genazzani: Serum tumor markers in the management of ovarian, endometrial and cervical cancer. Biomed Pharmacother, 58(1), 24-38 (2004) (Pubitemid 38117046)
86. K. Chang and I. Pastan: Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proc Natl Acad Sci U S A, 93(1), 136-40 (1996) (Pubitemid 26041483)
87. N. Scholler, N. Fu, Y. Yang, Z. Ye, G. E. Goodman, K. E. Hellstrom and I. Hellstrom: Soluble member(s) of the mesothelin/megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinoma. Proc Natl Acad Sci U S A, 96(20), 11531-6 (1999)
88. M. Chechlinska, J. Kaminska, J. Markowska, A. Kramar and J. Steffen: Peritoneal fluid cytokines and the differential diagnosis of benign and malignant ovarian tumors and residual/recurrent disease examination. Int J Biol Markers, 22(3), 172-80 (2007) (Pubitemid 350081625)
89. X. Fang, D. Gaudette, T. Furui, M. Mao, V. Estrella, A. Eder, T. Pustilnik, T. Sasagawa, R. Lapushin, S. Yu, R. B. Jaffe, J. R. Wiener, J. R. Erickson and G. B. Mills: Lysophospholipid growth factors in the initiation, progression, metastases, and management of ovarian cancer. Ann N Y Acad Sci, 905, 188-208 (2000) (Pubitemid 30255418)
90. M. Schummer, W. V. Ng, R. E. Bumgarner, P. S. Nelson, B. Schummer, D. W. Bednarski, L. Hassell, R. L. Baldwin, B. Y. Karlan and L. Hood: Comparative hybridization of an array of 21,500 ovarian cDNAs for the discovery of genes overexpressed in ovarian carcinomas. Gene, 238(2), 375-85 (1999) (Pubitemid 29446174)
91. S. C. Mok, J. Chao, S. Skates, K. Wong, G. K. Yiu, M. G. Muto, R. S. Berkowitz and D. W. Cramer: Prostasin, a potential serum marker for ovarian cancer: identification through microarray technology. J Natl Cancer Inst, 93(19), 1458-64 (2001) (Pubitemid 32982674)
92. J. H. Kim, S. J. Skates, T. Uede, K. K. Wong, J. O. Schorge, C. M. Feltmate, R. S. Berkowitz, D. W. Cramer and S. C. Mok: Osteopontin as a potential diagnostic biomarker for ovarian cancer. JAMA, 287(13), 1671-9 (2002) (Pubitemid 34289219)
93. E. P. Diamandis, G. M. Yousef, A. R. Soosaipillai and P. Bunting: Human kallikrein 6 (zyme/protease M/neurosin): a new serum biomarker of ovarian carcinoma. Clin Biochem, 33(7), 579-83 (2000) (Pubitemid 32012441)
94. A. Obermair, C. Tempfer, L. Hefler, O. Preyer, A. Kaider, R. Zeillinger, S. Leodolter and C. Kainz: Concentration of vascular endothelial growth factor (VEGF) in the serum of patients with suspected ovarian cancer. Br J Cancer, 77(11), 1870-4 (1998) (Pubitemid 28254626)
95. A. E. Lokshin, M. Winans, D. Landsittel, A. M. Marrangoni, L. Velikokhatnaya, F. Modugno, B. M. Nolen and E. Gorelik: Circulating IL-8 and anti-IL-8 autoantibody in patients with ovarian cancer. Gynecol Oncol, 102(2), 244-51 (2006) (Pubitemid 44041638)
96. T. K. Bera and I. Pastan: Mesothelin is not required for normal mouse development or reproduction. Mol Cell Biol, 20(8), 2902-6 (2000) (Pubitemid 30183509)
97. N. G. Ordonez: Value of mesothelin immunostaining in the diagnosis of mesothelioma. Mod Pathol, 16(3), 192-7 (2003) (Pubitemid 36337423)
98. P. Argani, C. Iacobuzio-Donahue, B. Ryu, C. Rosty, M. Goggins, R. E. Wilentz, S. R. Murugesan, S. D. Leach, E. Jaffee, C. J. Yeo, J. L. Cameron, S. E. Kern and R. H. Hruban: Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE). Clin Cancer Res, 7(12), 3862-8 (2001) (Pubitemid 34044602)
99. R. Hassan, R. J. Kreitman, I. Pastan and M. C. Willingham: Localization of Mesothelin in Epithelial Ovarian Cancer. Appl Immunohistochem Mol Morphol, 13(3), 243-247 (2005) (Pubitemid 41209017)
100. B. W. Robinson, J. Creaney, R. Lake, A. Nowak, A. W. Musk, N. de Klerk, P. Winzell, K. E. Hellstrom and I. Hellstrom: Mesothelin-family proteins and diagnosis of mesothelioma. Lancet, 362(9396), 1612-6 (2003) (Pubitemid 37443528)
101. M. W. McIntosh, C. Drescher, B. Karlan, N. Scholler, N. Urban, K. E. Hellstrom and I. Hellstrom: Combining CA 125 and SMR serum markers for diagnosis and early detection of ovarian carcinoma. Gynecol Oncol, 95(1), 9-15 (2004) (Pubitemid 39286271)
102. M. Ho, M. Onda, Q. C. Wang, R. Hassan, I. Pastan and M. O. Lively: Mesothelin is shed from tumor cells. Cancer Epidemiol Biomarkers Prev, 15(9), 1751 (2006)
103. I. Hellstrom, J. Raycraft, S. Kanan, N. Y. Sardesai, T. Verch, Y. Yang and K. E. Hellstrom: Mesothelin variant 1 is released from tumor cells as a diagnostic marker. Cancer Epidemiol Biomarkers Prev, 15(5), 1014-20 (2006) (Pubitemid 43823532)
104. H. L. Beyer, R. D. Geschwindt, C. L. Glover, L. Tran, I. Hellstrom, K. E. Hellstrom, M. C. Miller, T. Verch, W. J. Allard, H. I. Pass and N. Y. Sardesai: MESOMARK: a potential test for malignant pleural mesothelioma. Clin Chem, 53(4), 666-72 (2007) (Pubitemid 46580236)
105. W. F. Cheng, C. Y. Huang, M. C. Chang, Y. H. Hu, Y. C. Chiang, Y. L. Chen, C. Y. Hsieh and C. A. Chen: High mesothelin correlates with chemoresistance and poor survival in epithelial ovarian carcinoma. Br J Cancer, 100(7), 1144-53 (2009)
106. Y. Xu, Z. Shen, D. W. Wiper, M. Wu, R. E. Morton, P. Elson, A. W. Kennedy, J. Belinson, M. Markman and G. Casey: Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers. JAMA, 280(8), 719-23 (1998) (Pubitemid 28405297)
107. J. So, J. Navari, F. Q. Wang and D. A. Fishman: Lysophosphatidic acid enhances epithelial ovarian carcinoma invasion through the increased expression of interleukin-8. Gynecol Oncol, 95(2), 314-22 (2004) (Pubitemid 39445866)
108. X. Fang, M. Schummer, M. Mao, S. Yu, F. H. Tabassam, R. Swaby, Y. Hasegawa, J. L. Tanyi, R. LaPushin, A. Eder, R. Jaffe, J. Erickson and G. B. Mills: Lysophosphatidic acid is a bioactive mediator in ovarian cancer. Biochim Biophys Acta, 1582(1-3), 257-64 (2002) (Pubitemid 34634137)
109. A. M. Eder, T. Sasagawa, M. Mao, J. Aoki and G. B. Mills: Constitutive and lysophosphatidic acid (LPA)-induced LPA production: role of phospholipase D and phospholipase A2. Clin Cancer Res, 6(6), 2482-91 (2000) (Pubitemid 30399219)
110. J. L. Tanyi, Y. Hasegawa, R. Lapushin, A. J. Morris, J. K. Wolf, A. Berchuck, K. Lu, D. I. Smith, K. Kalli, L. C. Hartmann, K. McCune, D. Fishman, R. Broaddus, K. W. Cheng, E. N. Atkinson, J. M. Yamal, R. C. Bast, E. A. Felix, R. A. Newman and G. B. Mills: Role of decreased levels of lipid phosphate phosphatase-1 in accumulation of lysophosphatidic acid in ovarian cancer. Clin Cancer Res, 9(10 Pt 1), 3534-45 (2003) (Pubitemid 37169216)
111. J. L. Tanyi, A. J. Morris, J. K. Wolf, X. Fang, Y. Hasegawa, R. Lapushin, N. Auersperg, Y. J. Sigal, R. A. Newman, E. A. Felix, E. N. Atkinson and G. B. Mills: The human lipid phosphate phosphatase-3 decreases the growth, survival, and tumorigenesis of ovarian cancer cells: validation of the lysophosphatidic acid signaling cascade as a target for therapy in ovarian cancer. Cancer Res, 63(5), 1073-82 (2003) (Pubitemid 36278441)
112. D. R. Senger, C. A. Perruzzi and A. Papadopoulos: Elevated expression of secreted phosphoprotein I (osteopontin, 2ar) as a consequence of neoplastic transformation. Anticancer Res, 9(5), 1291-9 (1989)
113. G. F. Weber, S. Ashkar, M. J. Glimcher and H. Cantor: Receptor-ligand interaction between CD44 and osteopontin (Eta-1). Science, 271(5248), 509-12 (1996) (Pubitemid 26044470)
114. M. D. McKee and A. Nanci: Secretion of Osteopontin by macrophages and its accumulation at tissue surfaces during wound healing in mineralized tissues: a potential requirement for macrophage adhesion and phagocytosis. Anat Rec, 245(2), 394-409 (1996) (Pubitemid 26000721)
115. T. Ue, H. Yokozaki, Y. Kitadai, S. Yamamoto, W. Yasui, T. Ishikawa and E. Tahara: Co-expression of osteopontin and CD44v9 in gastric cancer. Int J Cancer, 79(2), 127-32 (1998) (Pubitemid 28201682)
116. J. O. Schorge, R. D. Drake, H. Lee, S. J. Skates, R. Rajanbabu, D. S. Miller, J. H. Kim, D. W. Cramer, R. S. Berkowitz and S. C. Mok: Osteopontin as an adjunct to CA125 in detecting recurrent ovarian cancer. Clin Cancer Res, 10(10), 3474-8 (2004) (Pubitemid 38685455)
117. I. Visintin, Z. Feng, G. Longton, D. C. Ward, A. B. Alvero, Y. Lai, J. Tenthorey, A. Leiser, R. Flores-Saaib, H. Yu, M. Azori, T. Rutherford, P. E. Schwartz and G. Mor: Diagnostic markers for early detection of ovarian cancer. Clin Cancer Res, 14(4), 1065-72 (2008) (Pubitemid 351302552)
118. N. Emami and E. P. Diamandis: Utility of kallikreinrelated peptidases (KLKs) as cancer biomarkers. Clin Chem, 54(10), 1600-7 (2008)
119. M. Paliouras, C. Borgono and E. P. Diamandis: Human tissue kallikreins: the cancer biomarker family. Cancer Lett, 249(1), 61-79 (2007) (Pubitemid 46427999)
120. N. M. White, M. Mathews, G. M. Yousef, A. Prizada, D. Fontaine, P. Ghatage, C. Popadiuk, L. Dawson and J. J. Dore: Human kallikrein related peptidases 6 and 13 in combination withCA125 is a more sensitive test for ovarian cancer than CA125 alone. Cancer Biomark, 5(6), 279-87 (2009)
121. S. J. Skates, U. Menon, N. MacDonald, A. N. Rosenthal, D. H. Oram, R. C. Knapp and I. J. Jacobs: Calculation of the risk of ovarian cancer from serial CA-125 values for preclinical detection in postmenopausal women. J Clin Oncol, 21(10 Suppl), 206s-210s (2003)
122. G. Horvath, G. A. Jarverud, S. Jarverud and I. Horvath: Human ovarian carcinomas detected by specific odor. Integr Cancer Ther, 7(2), 76-80 (2008) (Pubitemid 351806533)
123. G. Horvath, J. Chilo and T. Lindblad: Different volatile signals emitted by human ovarian carcinoma and healthy tissue. Future Oncol, 6(6), 1043-9 (2010)
124. R. dos Reis, M. Frumovitz, M. R. Milam, E. Capp, C. C. Sun, R. L. Coleman and P. T. Ramirez: Adenosquamous carcinoma versus adenocarcinoma in early-stage cervical cancer patients undergoing radical hysterectomy: an outcomes analysis. Gynecol Oncol, 107(3), 458-63 (2007) (Pubitemid 350160856)
125. S. C. Pak, M. Martens, R. Bekkers, A. J. Crandon, R. Land, J. L. Nicklin, L. C. Perrin and A. Obermair: Pap smear screening history of women with squamous cell carcinoma and adenocarcinoma of the cervix. Aust N Z J Obstet Gynaecol, 47(6), 504-7 (2007) (Pubitemid 350075929)
126. W. G. McCluggage, V. P. Sumathi, H. A. McBride and A. Patterson: A panel of immunohistochemical stains, including carcinoembryonic antigen, vimentin, and estrogen receptor, aids the distinction between primary endometrial and endocervical adenocarcinomas. Int J Gynecol Pathol, 21(1), 11-5 (2002) (Pubitemid 34008347)
127. J. M. Duk, J. G. Aalders, G. J. Fleuren, M. Krans and H. W. De Bruijn: Tumor markers CA 125, squamous cell carcinoma antigen, and carcinoembryonic antigen in patients with adenocarcinoma of the uterine cervix. Obstet Gynecol, 73(4), 661-8 (1989) (Pubitemid 19086983)
128. S. N. Bae, S. E. Namkoong, J. K. Jung, C. J. Kim, J. S. Park, J. W. Kim, J. M. Lee and S. J. Kim: Prognostic significance of pretreatment squamous cell carcinoma antigen and carcinoembryonic antigen in squamous cell carcinoma of the uterine cervix. Gynecol Oncol, 64(3), 418-24 (1997) (Pubitemid 27120429)
129. R. Molina, X. Filella, J. M. Auge, E. Bosch, A. Torne, J. Pahisa, J. A. Lejarcegui, A. Rovirosa, B. Mellado, J. Ordi and A. Biete: CYFRA 21.1 in patients with cervical cancer: comparison with SCC and CEA. Anticancer Res, 25(3A), 1765-71 (2005) (Pubitemid 40896800)
130. S. C. Tsai, C. H. Kao and S. J. Wang: Study of a new tumor marker, CYFRA 21-1, in squamous cell carcinoma of the cervix, and comparison with squamous cell carcinoma antigen. Neoplasma, 43(1), 27-9 (1996)
131. J. M. Bonfrer, K. N. Gaarenstroom, G. G. Kenter, C. M. Korse, A. A. Hart, M. P. Gallee, T. J. Helmerhorst and P. Kenemans: Prognostic significance of serum fragments of cytokeratin 19 measured by Cyfra 21-1 in cervical cancer. Gynecol Oncol, 55(3 Pt 1), 371-5 (1994)
132. N. Inaba, Y. Negishi, I. Fukasawa, Y. Okajima, Y. Ota, K. Tanaka, H. Matsui, H. Iwasaki, H. Sudo, N. Tanaka and et al.: Cytokeratin fragment 21-1 in gynecologic malignancy: comparison with cancer antigen 125 and squamous cell carcinoma-related antigen. Tumour Biol, 16(6), 345-52 (1995)
133. M. Ferdeghini, A. Gadducci, C. Annicchiarico, C. Prontera, G. Malagnino, C. Castellani, V. Facchini and R. Bianchi: Serum CYFRA 21-1 assay in squamous cell carcinoma of the cervix. Anticancer Res, 13(5C), 1841-4 (1993) (Pubitemid 24008114)
134. U. Hasholzner, L. Baumgartner, P. Stieber, W. Meier, K. Hofmann and A. Fateh-Moghadam: Significance of the tumour markers CA 125 II, CA 72-4, CASA and CYFRA 21-1 in ovarian carcinoma. Anticancer Res, 14(6B), 2743-6 (1994)
135. C. Tempfer, L. Hefler, H. Heinzl, A. Loesch, G. Gitsch, H. Rumpold and C. Kainz: CYFRA 21-1 serum levels in women with adnexal masses and inflammatory diseases. Br J Cancer, 78(8), 1108-12 (1998) (Pubitemid 28463991)
136. A. Gadducci, M. Ferdeghini, S. Cosio, A. Fanucchi, R. Cristofani and A.
137. R. G. Moore, A. K. Brown, M. C. Miller, D. Badgwell, Z. Lu, W. J. Allard, C. O. Granai, R. C. Bast, Jr. and K. Lu: Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenocarcinoma of the uterus. Gynecol Oncol, 110(2), 196-201 (2008)
138. J. Li, S. Dowdy, T. Tipton, K. Podratz, W. G. Lu, X. Xie and S. W. Jiang: HE4 as a biomarker for ovarian and endometrial cancer management. Expert Rev Mol Diagn, 9(6), 555-66 (2009)
139. A. D. Santin, E. P. Diamandis, S. Bellone, A. Soosaipillai, S. Cane, M. Palmieri, A. Burnett, J. J. Roman and S. Pecorelli: Human kallikrein 6: a new potential serum biomarker for uterine serous papillary cancer. Clin Cancer Res, 11(9), 3320-5 (2005) (Pubitemid 40627882)
140. A. D. Santin, E. P. Diamandis, S. Bellone, M. Marizzoni, E. Bandiera, M. Palmieri, C. Papasakelariou, D. Katsaros, A. Burnett and S. Pecorelli: Overexpression of kallikrein 10 (hK10) in uterine serous papillary carcinomas. Am J Obstet Gynecol, 194(5), 1296-302 (2006)
141. A. D. Santin, F. Zhan, S. Bellone, M. Palmieri, S. Cane, M. Gokden, J. J. Roman, T. J. O'Brien, E. Tian, M. J. Cannon, J. Shaughnessy, Jr. and S. Pecorelli: Discrimination between uterine serous papillary carcinomas and ovarian serous papillary tumours by gene expression profiling. Br J Cancer, 90(9), 1814-24 (2004) (Pubitemid 38725659)
142. E. Cocco, S. Bellone, K. El-Sahwi, M. Cargnelutti, F. Casagrande, N. Buza, F. A. Tavassoli, E. R. Siegel, I. Visintin, E. Ratner, D. A. Silasi, M. Azodi, P. E. Schwartz, T. J. Rutherford, S. Pecorelli and A. D. Santin: Serum amyloid A (SAA): a novel biomarker for uterine serous papillary cancer. Br J Cancer, 101(2), 335-41 (2009)
143. A. Shaaban and M. Rezvani: Ovarian cancer: detection and radiologic staging. Clin Obstet Gynecol, 52(1), 73-93 (2009)
144. D. L. Clarke-Pearson: Clinical practice. Screening for ovarian cancer. N Engl J Med, 361(2), 170-7 (2009)
145. D. G. Mutch: Ovarian cancer: to screen or not to screen. Obstet Gynecol, 113(4), 772-4 (2009)
146. U. Menon, A. Gentry-Maharaj, R. Hallett, A. Ryan, M. Burnell, A. Sharma, S. Lewis, S. Davies, S. Philpott, A. Lopes, K. Godfrey, D. Oram, J. Herod, K. Williamson, M. W. Seif, I. Scott, T. Mould, R. Woolas, J. Murdoch, S. Dobbs, N. N. Amso, S. Leeson, D. Cruickshank, A. McGuire, S. Campbell, L. Fallowfield, N. Singh, A. Dawnay, S. J. Skates, M. Parmar and I. Jacobs: Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncol, 10(4), 327-40 (2009)